Micheli F E, Pardal M M, Giannaula R, Gatto M, Parera I, Paradiso G, Torres M, Pikielny R, Pardal J
Neurology Department, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina.
Mov Disord. 1989;4(2):139-46. doi: 10.1002/mds.870040205.
Over the last few years, cases of movement disorders induced by flunarizine and cinnarizine have been increasingly reported. We describe a series of 101 patients, whose ages ranged from 37 to 84 years (mean 69.1), developing abnormal movements frequently associated with depression, secondary to treatment with either or both drugs. Symptoms closely resembled those induced by neuroleptic drugs and remitted on drug discontinuance in all but five cases after 5-22 months' follow-up. Whether or not such undesirable side effects are attributable to calcium antagonism and/or dopamine receptor blockade, long-term treatment with flunarizine or cinnarizine should be discouraged, particularly in the elderly.
在过去几年中，越来越多地报道了由氟桂利嗪和桂利嗪引起的运动障碍病例。我们描述了一系列101例患者，年龄在37至84岁之间（平均69.1岁），在使用这两种药物中的一种或两种进行治疗后，出现了常与抑郁相关的异常运动。症状与抗精神病药物引起的症状非常相似，除5例患者外，其余患者在5至22个月的随访后停药症状缓解。无论这些不良副作用是否归因于钙拮抗作用和/或多巴胺受体阻滞，都应避免长期使用氟桂利嗪或桂利嗪进行治疗，尤其是在老年人中。
